

## Suvorexant Formulation

Version 7.0      Revision Date: 20.03.2023      SDS Number: 21549-00021      Date of last issue: 01.10.2022  
Date of first issue: 14.10.2014

---

### Section 1: Identification

Product name : Suvorexant Formulation

#### Manufacturer or supplier's details

Company : MSD

Address : 33 Whakatiki Street - Private Bag 908  
Upper Hutt - New Zealand

Telephone : +1-908-740-4000

Emergency telephone number : +1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use :  
Not applicable

---

### Section 2: Hazard identification

#### GHS Classification

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Central nervous system)

Hazardous to the aquatic environment - chronic hazard : Category 3

#### GHS label elements

Hazard pictograms :



Signal word : Warning

Hazard statements : H373 May cause damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.  
H412 Harmful to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**  
P273 Avoid release to the environment.

**Response:**  
P314 Get medical advice/ attention if you feel unwell.

**Disposal:**

## Suvorexant Formulation

Version 7.0      Revision Date: 20.03.2023      SDS Number: 21549-00021      Date of last issue: 01.10.2022  
 Date of first issue: 14.10.2014

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

Dust contact with the eyes can lead to mechanical irritation.  
 Contact with dust can cause mechanical irritation or drying of the skin.  
 May form explosive dust-air mixture during processing, handling or other means.

**Section 3: Composition/information on ingredients**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Suvorexant	1030377-33-3	>= 2.5 -< 10
Magnesium stearate	557-04-0	>= 1 -< 10

**Section 4: First-aid measures**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
 When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
 Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap.  
 Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.  
 Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
 Get medical attention if symptoms occur.  
 Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : Contact with dust can cause mechanical irritation or drying of the skin.  
 Dust contact with the eyes can lead to mechanical irritation.  
 May cause damage to organs through prolonged or repeated exposure if swallowed.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

**Section 5: Fire-fighting measures**

Suitable extinguishing media : Water spray  
 Alcohol-resistant foam  
 Carbon dioxide (CO<sub>2</sub>)  
 Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.

## Suvorexant Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01.10.2022
7.0	20.03.2023	21549-00021	Date of first issue: 14.10.2014

---

Exposure to combustion products may be a hazard to health.

- Hazardous combustion products : Carbon oxides  
Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.
- 

**Section 6: Accidental release measures**

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
- 

**Section 7: Handling and storage**

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment

## Suvorexant Formulation

Version 7.0      Revision Date: 20.03.2023      SDS Number: 21549-00021      Date of last issue: 01.10.2022  
 Date of first issue: 14.10.2014

- Minimize dust generation and accumulation.  
 Keep container closed when not in use.  
 Keep away from heat and sources of ignition.  
 Take precautionary measures against static discharges.  
 Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
 When using do not eat, drink or smoke.  
 Wash contaminated clothing before re-use.  
 The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labelled containers.  
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents

## Section 8: Exposure controls/personal protection

## Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Suvorexant	1030377-33-3	TWA	14 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	140 µg/100 cm <sup>2</sup>	Internal
Magnesium stearate	557-04-0	WES-TWA	10 mg/m <sup>3</sup>	NZ OEL
		TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH

- Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
 Minimize open handling.

**Personal protective equipment**

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Particulates type

## Suvorexant Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01.10.2022
7.0	20.03.2023	21549-00021	Date of first issue: 14.10.2014

---

## Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.

---

## Section 9: Physical and chemical properties

Appearance : powder

Colour : No data available

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : Not applicable

Relative vapour density : Not applicable

Relative density : No data available

**Suvorexant Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 01.10.2022
7.0	20.03.2023	21549-00021	Date of first issue: 14.10.2014

---

Density	:	No data available
Solubility(ies)	:	
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

---

**Section 10: Stability and reactivity**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

**Section 11: Toxicological information**

Exposure routes	:	Inhalation Skin contact Ingestion Eye contact
-----------------	---	--

**Acute toxicity**

Not classified based on available information.

**Components:****Suvorexant:**

Acute oral toxicity	:	LD50 (Rat): > 1,200 mg/kg LD50 (Dog): > 1,125 mg/kg
---------------------	---	--

---

**Suvorexant Formulation**

Version 7.0      Revision Date: 20.03.2023      SDS Number: 21549-00021      Date of last issue: 01.10.2022  
Date of first issue: 14.10.2014

---

LDLo (Mouse): 2,000 mg/kg

**Magnesium stearate:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity  
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg  
Remarks: Based on data from similar materials

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Suvorexant:**

Species : Rabbit  
Result : No skin irritation

**Magnesium stearate:**

Species : Rabbit  
Result : No skin irritation  
Remarks : Based on data from similar materials

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Suvorexant:**

Species : Bovine cornea  
Result : Mild eye irritation  
Method : Bovine cornea (BCOP)

**Magnesium stearate:**

Species : Rabbit  
Result : No eye irritation  
Remarks : Based on data from similar materials

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

## Suvorexant Formulation

Version 7.0      Revision Date: 20.03.2023      SDS Number: 21549-00021      Date of last issue: 01.10.2022  
 Date of first issue: 14.10.2014

**Components:****Suvorexant:**

Test Type	:	Local lymph node assay (LLNA)
Species	:	Mouse
Assessment	:	Does not cause skin sensitisation.
Result	:	negative

**Magnesium stearate:**

Test Type	:	Maximisation Test
Exposure routes	:	Skin contact
Species	:	Guinea pig
Method	:	OECD Test Guideline 406
Result	:	negative
Remarks	:	Based on data from similar materials

**Chronic toxicity****Germ cell mutagenicity**

Not classified based on available information.

**Components:****Suvorexant:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: Alkaline elution assay Test system: rat hepatocytes Result: negative
		Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: negative
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse Result: negative
		Test Type: Micronucleus test Species: Rat Result: negative

**Magnesium stearate:**

Genotoxicity in vitro	:	Test Type: In vitro mammalian cell gene mutation test Result: negative Remarks: Based on data from similar materials
		Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473 Result: negative Remarks: Based on data from similar materials



## Suvorexant Formulation

Version 7.0      Revision Date: 20.03.2023      SDS Number: 21549-00021      Date of last issue: 01.10.2022  
 Date of first issue: 14.10.2014

Test Type: Bacterial reverse mutation assay (AMES)  
 Result: negative  
 Remarks: Based on data from similar materials

**Carcinogenicity**

Not classified based on available information.

**Components:****Suvorexant:**

Species : Mouse  
 Application Route : Oral  
 Exposure time : 6 month(s)  
 Result : negative

Species : Rat  
 Application Route : Oral  
 Exposure time : 2 Years  
 Result : negative

**Reproductive toxicity**

Not classified based on available information.

**Components:****Suvorexant:**

Effects on fertility : Test Type: Fertility/early embryonic development  
 Species: Rat, male and female  
 Application Route: Oral  
 General Toxicity - Parent: NOAEL: >= 325 mg/kg body weight  
 Result: negative

Effects on foetal development : Test Type: Embryo-foetal development  
 Species: Rabbit, female  
 Application Route: Oral  
 Developmental Toxicity: NOAEL: 150 mg/kg body weight  
 Result: negative

Test Type: Embryo-foetal development  
 Species: Rat  
 Application Route: Oral  
 Developmental Toxicity: NOAEL: 80 mg/kg body weight  
 Result: negative

**Magnesium stearate:**

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
 Species: Rat  
 Application Route: Ingestion  
 Method: OECD Test Guideline 422  
 Result: negative  
 Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development

## Suvorexant Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01.10.2022
7.0	20.03.2023	21549-00021	Date of first issue: 14.10.2014

---

ment	Species: Rat
	Application Route: Ingestion
	Result: negative
	Remarks: Based on data from similar materials

**STOT - single exposure**

Not classified based on available information.

**Components:****Suvorexant:**

Remarks	: Based on human experience.
---------	------------------------------

**STOT - repeated exposure**

May cause damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

**Components:****Suvorexant:**

Exposure routes	: Ingestion
Target Organs	: Central nervous system
Assessment	: May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Suvorexant:**

Species	: Rat
NOAEL	: 325 mg/kg
LOAEL	: 1,200 mg/kg
Application Route	: Oral
Exposure time	: 30 d
Target Organs	: Blood, Pancreas

Species	: Dog
NOAEL	: 50 mg/kg
LOAEL	: 125 mg/kg
Application Route	: Oral
Exposure time	: 30 d
Target Organs	: Blood, Liver, Central nervous system

Species	: Rat
NOAEL	: 75 mg/kg
LOAEL	: 300 mg/kg
Application Route	: Oral
Exposure time	: 180 d
Target Organs	: Pancreas, Blood, Stomach

Species	: Dog
NOAEL	: 50 mg/kg
LOAEL	: 125 mg/kg

## Suvorexant Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01.10.2022
7.0	20.03.2023	21549-00021	Date of first issue: 14.10.2014

---

Application Route	:	Oral
Exposure time	:	270 d
Target Organs	:	Blood
Species	:	Rat
NOAEL	:	40 mg/kg
LOAEL	:	80 mg/kg
Application Route	:	Oral
Exposure time	:	18 Months
Target Organs	:	Eye, Central nervous system

**Magnesium stearate:**

Species	:	Rat
NOAEL	:	> 100 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days
Remarks	:	Based on data from similar materials

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Suvorexant:**

Ingestion	:	Symptoms: Drowsiness, Headache, abnormal dreams, Fatigue, Dizziness, dry mouth, Nausea, liver function change, upper respiratory tract infection, urinary tract infection, Cough, Diarrhoea, Palpitation, tachycardia
-----------	---	---

**Section 12: Ecological information****Ecotoxicity****Components:****Suvorexant:**

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Mysidopsis bahia (opossum shrimp)): 0.56 mg/l Exposure time: 96 h Method: US-EPA OPPTS 850.1035
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 5 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
	:	NOEC (Pseudokirchneriella subcapitata (green algae)): 2.5 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
M-Factor (Acute aquatic toxicity)	:	1

## Suvorexant Formulation

Version 7.0      Revision Date: 20.03.2023      SDS Number: 21549-00021      Date of last issue: 01.10.2022  
 Date of first issue: 14.10.2014

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.14 mg/l  
 Exposure time: 32 d  
 Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.5 mg/l  
 Exposure time: 21 d  
 Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l  
 Exposure time: 3 h  
 Test Type: Respiration inhibition  
 Method: OECD Test Guideline 209

NOEC: 1,000 mg/l  
 Exposure time: 3 h  
 Test Type: Respiration inhibition  
 Method: OECD Test Guideline 209

**Magnesium stearate:**

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l  
 Exposure time: 48 h  
 Method: DIN 38412  
 Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l  
 Exposure time: 47 h  
 Test substance: Water Accommodated Fraction  
 Method: Directive 67/548/EEC, Annex V, C.2.  
 Remarks: Based on data from similar materials  
 No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
 Exposure time: 72 h  
 Test substance: Water Accommodated Fraction  
 Method: OECD Test Guideline 201  
 Remarks: Based on data from similar materials  
 No toxicity at the limit of solubility

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
 Exposure time: 72 h  
 Test substance: Water Accommodated Fraction  
 Method: OECD Test Guideline 201  
 Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l  
 Exposure time: 16 h  
 Test substance: Water Accommodated Fraction  
 Remarks: Based on data from similar materials

## Suvorexant Formulation

Version 7.0      Revision Date: 20.03.2023      SDS Number: 21549-00021      Date of last issue: 01.10.2022  
 Date of first issue: 14.10.2014

---

**Persistence and degradability****Components:****Suvorexant:**

Biodegradability : Result: Not readily biodegradable.  
 Biodegradation: 81 %  
 Exposure time: 28 d  
 Method: OECD Test Guideline 314

Stability in water : Hydrolysis: < 10 % (5 d)  
 Method: OECD Test Guideline 111

**Magnesium stearate:**

Biodegradability : Result: Not biodegradable  
 Remarks: Based on data from similar materials

**Bioaccumulative potential****Components:****Suvorexant:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
 Bioconcentration factor (BCF): 358  
 Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.04

**Magnesium stearate:**

Partition coefficient: n-octanol/water : log Pow: > 4

**Mobility in soil**

No data available

**Other adverse effects**

No data available

---

**Section 13: Disposal considerations****Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.  
 Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
 If not otherwise specified: Dispose of as unused product.

---

**Section 14: Transport information****International Regulations****UNRTDG**

UN number : Not applicable

---

**Suvorexant Formulation**

Version      Revision Date:      SDS Number:      Date of last issue: 01.10.2022  
7.0          20.03.2023          21549-00021      Date of first issue: 14.10.2014

---

Proper shipping name      :    Not applicable  
Class                            :    Not applicable  
Subsidiary risk             :    Not applicable  
Packing group              :    Not applicable  
Labels                        :    Not applicable

**IATA-DGR**

UN/ID No.                    :    Not applicable  
Proper shipping name      :    Not applicable  
Class                            :    Not applicable  
Subsidiary risk             :    Not applicable  
Packing group              :    Not applicable  
Labels                        :    Not applicable  
Packing instruction (cargo :    Not applicable  
aircraft)  
Packing instruction (passen- :    Not applicable  
ger aircraft)

**IMDG-Code**

UN number                    :    Not applicable  
Proper shipping name      :    Not applicable  
Class                            :    Not applicable  
Subsidiary risk             :    Not applicable  
Packing group              :    Not applicable  
Labels                        :    Not applicable  
EmS Code                     :    Not applicable  
Marine pollutant            :    Not applicable

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**National Regulations****NZS 5433**

UN number                    :    Not applicable  
Proper shipping name      :    Not applicable  
Class                            :    Not applicable  
Subsidiary risk             :    Not applicable  
Packing group              :    Not applicable  
Labels                        :    Not applicable  
Hazchem Code              :    Not applicable

**Special precautions for user**

Not applicable

---

**Section 15: Regulatory information**

**Safety, health and environmental regulations/legislation specific for the substance or mixture**

**HSNO Approval Number**

HSR100425 Pharmaceutical Active Ingredients Group Standard

**HSW Controls**

Certified handler certificate not required.  
Tracking hazardous substance not required.

## Suvorexant Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01.10.2022
7.0	20.03.2023	21549-00021	Date of first issue: 14.10.2014

---

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

**The components of this product are reported in the following inventories:**

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

---

### Section 16: Other information

Revision Date : 20.03.2023

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
 NZ OEL : New Zealand. Workplace Exposure Standards for Atmospheric Contaminants

ACGIH / TWA : 8-hour, time-weighted average  
 NZ OEL / WES-TWA : Workplace Exposure Standard - Time Weighted average

AIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIcC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances

**Suvorexant Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 01.10.2022
7.0	20.03.2023	21549-00021	Date of first issue: 14.10.2014

---

es; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN